Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 147, Issue 8, Pages 2279-2292Publisher
WILEY
DOI: 10.1002/ijc.33050
Keywords
breast cancer; macrophages; metastasis; myeloid-derived suppressor cells; p38 kinase; tumor microenvironment
Categories
Funding
- Congressionally Directed Medical Research Programs [BC151886]
- METAvivor
- National Cancer Institute [F31CA228396, R01CA172105, R25CA181003, T32CA085183]
- CDMRP [BC151886, 893245] Funding Source: Federal RePORTER
Ask authors/readers for more resources
Patients with metastatic breast cancer (MBC) have limited therapeutic options and novel treatments are critically needed. Prior research implicates tumor-induced mobilization of myeloid cell populations in metastatic progression, as well as being an unfavorable outcome in MBC; however, the underlying mechanisms for these relationships remain unknown. Here, we provide evidence for a novel mechanism by which p38 promotes metastasis. Using triple-negative breast cancer models, we showed that a selective inhibitor of p38 (p38i) significantly reduced tumor growth, angiogenesis, and lung metastasis. Importantly, p38i decreased the accumulation of myeloid populations, namely, myeloid-derived suppressor cells (MDSCs) and CD163(+) tumor-associated macrophages (TAMs). p38 controlled the expression of tumor-derived chemokines/cytokines that facilitated the recruitment of protumor myeloid populations. Depletion of MDSCs was accompanied by reduced TAM infiltration and phenocopied the antimetastatic effects of p38i. Reciprocally, p38i increased tumor infiltration by cytotoxic CD8(+) T cells. Furthermore, the CD163(+)/CD8(+) expression ratio inversely correlated with metastasis-free survival in breast cancer, suggesting that targeting p38 may improve clinical outcomes. Overall, our study highlights a previously unknown p38-driven pathway as a therapeutic target in MBC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available